A new civil rights lawsuit against the Missouri Department of Corrections is forcing a long-overdue reckoning with how the state treats incarcerated people struggling with opioid addiction. The suit, filed in federal court on March 5, alleges that Missouri prisons systematically punish people for their addictions rather than providing constitutionally required medical treatment.
The lawsuit centers on the state’s failure to scale its medication-assisted treatment program — widely considered the gold standard for opioid use disorder — despite years of promises to do so. As of early 2026, only 841 people in Missouri’s prison system have access to medications like buprenorphine and methadone, out of a population where substance use disorder affects thousands.
Punishment Over Treatment
According to the complaint, incarcerated individuals who exhibit signs of opioid withdrawal are routinely placed in solitary confinement rather than referred to medical staff. The suit describes cases where people experiencing acute withdrawal symptoms — including vomiting, seizures, and severe dehydration — were left in isolation cells for days without medical intervention.
The Missouri prison system has long struggled with drug interdiction. Fentanyl and methamphetamine have flooded state correctional facilities through mail, visitation, and, in some cases, staff members. But the lawsuit argues that the state’s response has focused almost exclusively on punishment and detection rather than addressing the underlying medical condition.
Disciplinary records obtained by the plaintiffs’ attorneys show that hundreds of people received infractions for “substance abuse” in 2025 alone — infractions that resulted in loss of good-time credits, restricted privileges, and extended stays in restrictive housing. For many, these punishments extended their time behind bars for what medical professionals classify as a chronic brain disorder.
The MAT Gap
Medication-assisted treatment, or MAT, combines FDA-approved medications with counseling and behavioral therapies to treat opioid use disorder. Research consistently shows that MAT reduces overdose deaths, decreases criminal recidivism, and improves long-term recovery outcomes. The federal government and most medical organizations consider it the standard of care.
Missouri began piloting a limited MAT program in 2023, starting with just 121 participants across the state’s 20 adult correctional facilities. Officials projected they would scale the program to 841 people by summer 2026 — a number that advocates say is woefully inadequate given the scope of the crisis.
By comparison, states like California and Rhode Island have implemented system-wide MAT programs that provide treatment to any incarcerated person who needs it, regardless of facility capacity. Those programs have shown dramatic reductions in overdose deaths both inside prisons and in the critical weeks following release.
Deadly Consequences
The human cost of Missouri’s approach is measured in lives. The state recorded 14 in-custody deaths linked to drug overdoses in 2025, according to data compiled by the Bureau of Justice Statistics. That figure likely undercounts the true toll, as many overdose deaths in correctional settings are classified under broader categories like “medical emergency” or “undetermined cause.”
The period immediately following release is even more dangerous. People who have been incarcerated and deprived of opioid access have drastically reduced tolerance. Without a treatment bridge — a continuation of MAT from prison to community — the risk of fatal overdose in the first two weeks after release is 129 times higher than for the general population.
Missouri does not currently offer a standardized reentry MAT program. People who were receiving treatment inside are often cut off on their release date, with no prescription, no provider referral, and no supply of medication to bridge the gap. For families trying to support a loved one during incarceration, the lack of treatment continuity is a source of constant fear.
A National Problem
Missouri is far from alone. A 2025 survey by the Prison Policy Initiative found that fewer than half of state prison systems offer MAT to all people who need it, and many restrict access to those who were already on medication at the time of arrest. County jails are even further behind — unlike prisons, which hold sentenced individuals, jails process millions of bookings annually and often lack the infrastructure for sustained treatment programs.
The legal landscape is shifting, however. Federal courts in Massachusetts, Oregon, and Washington have ruled that denying MAT to incarcerated people constitutes cruel and unusual punishment under the Eighth Amendment. The Missouri lawsuit seeks to establish the same precedent in the Eighth Circuit, which covers seven Midwestern states.
If successful, the case could force Missouri to overhaul its approach to addiction treatment behind bars — and set a binding precedent for states across the region, including facilities in St. Louis and other major population centers where the opioid crisis has hit hardest.
Looking Ahead
The Missouri Department of Corrections issued a brief statement acknowledging the lawsuit and stating that it “takes the health and safety of all individuals in its custody seriously.” The department did not address specific allegations in the complaint.
A hearing on the plaintiffs’ motion for a preliminary injunction — which would require the state to immediately expand MAT access — is scheduled for late April. Legal observers expect the case to draw significant attention from corrections officials and civil rights organizations nationwide.
For the thousands of people inside Missouri’s prisons who are battling addiction without adequate medical support, the lawsuit represents something rare in the corrections system: a chance that someone outside the walls is listening.
